Bio News
China’s semi-invasive brain-computer interface (BCI) recorded more than 90% accuracy in a clinical trial involving 32 patients and received marketing approval. The technology, which attracted 7 billion yuan in investment in the first half of the year alone, demonstrated efficacy in 66% of patients with treatment-resistant mental disorders. The number of invasive BCI implantation cases is expected to increase to 36 in the future.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
